Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy

ABSTRACT Objective To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). Subjects and methods A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. Results From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). Conclusions Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes.

Saved in:
Bibliographic Details
Main Authors: Súss,Shirlei Kugler Aiçar, Mesa Jr.,Cleo Otaviano, Carvalho,Gisah Amaral de, Miasaki,Fabíola Yukiko, Chaves,Carolina Perez, Fuser,Dominique Cochat, Corbo,Rossana, Momesso,Denise, Bulzico,Daniel A., Graf,Hans, Vaisman,Fernanda
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Endocrinologia e Metabologia 2018
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200149
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2359-39972018000200149
record_format ojs
spelling oai:scielo:S2359-399720180002001492018-05-07Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapySúss,Shirlei Kugler AiçarMesa Jr.,Cleo OtavianoCarvalho,Gisah Amaral deMiasaki,Fabíola YukikoChaves,Carolina PerezFuser,Dominique CochatCorbo,RossanaMomesso,DeniseBulzico,Daniel A.Graf,HansVaisman,Fernanda Thyroid carcinoma radioiodine ablation low activity ABSTRACT Objective To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). Subjects and methods A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. Results From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). Conclusions Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArchives of Endocrinology and Metabolism v.62 n.2 20182018-03-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200149en10.20945/2359-3997000000025
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Súss,Shirlei Kugler Aiçar
Mesa Jr.,Cleo Otaviano
Carvalho,Gisah Amaral de
Miasaki,Fabíola Yukiko
Chaves,Carolina Perez
Fuser,Dominique Cochat
Corbo,Rossana
Momesso,Denise
Bulzico,Daniel A.
Graf,Hans
Vaisman,Fernanda
spellingShingle Súss,Shirlei Kugler Aiçar
Mesa Jr.,Cleo Otaviano
Carvalho,Gisah Amaral de
Miasaki,Fabíola Yukiko
Chaves,Carolina Perez
Fuser,Dominique Cochat
Corbo,Rossana
Momesso,Denise
Bulzico,Daniel A.
Graf,Hans
Vaisman,Fernanda
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
author_facet Súss,Shirlei Kugler Aiçar
Mesa Jr.,Cleo Otaviano
Carvalho,Gisah Amaral de
Miasaki,Fabíola Yukiko
Chaves,Carolina Perez
Fuser,Dominique Cochat
Corbo,Rossana
Momesso,Denise
Bulzico,Daniel A.
Graf,Hans
Vaisman,Fernanda
author_sort Súss,Shirlei Kugler Aiçar
title Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_short Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_full Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_fullStr Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_full_unstemmed Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_sort clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mci for ablation or without radioactive iodine therapy
description ABSTRACT Objective To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). Subjects and methods A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. Results From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). Conclusions Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes.
publisher Sociedade Brasileira de Endocrinologia e Metabologia
publishDate 2018
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200149
work_keys_str_mv AT sussshirleikugleraicar clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT mesajrcleootaviano clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT carvalhogisahamaralde clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT miasakifabiolayukiko clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT chavescarolinaperez clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT fuserdominiquecochat clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT corborossana clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT momessodenise clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT bulzicodaniela clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT grafhans clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT vaismanfernanda clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
_version_ 1756441396730920960